Table 3.

Relationship between use of statins and breast cancer risk by solubility and for the most commonly used statin medications

	Controls (n = 877)		Ductal cases (n = 891)				Lobular cases (n = 1,036)
	No.	%	No.	%	OR	95% CI	No.	%	OR	95% CI
Never use	674	76.9	664	74.8	1.00	reference	782	75.6	1.00	reference
Hydrophilic statins
Current use	13	1.5	18	2.0	1.56	0.75 - 3.24	21	2.0	1.65	0.81 - 3.38
Lipophilic statins
Current use	157	17.9	166	18.7	1.13	0.88 - 1.45	196	18.9	1.21	0.95 - 1.54
6mo - <5yrs	84	9.6	76	8.6	0.95	0.68 - 1.33	104	10.1	1.17	0.86 - 1.61
5yrs - <10yrs	44	5	45	5.1	1.09	0.70 - 1.69	44	4.3	0.96	0.62 - 1.50
≥ 10 yrs	28	3.2	43	4.8	1.74	1.05 - 2.86	45	4.4	1.68	1.02 - 2.76
p-value for trend					p = 0.119				p = 0.094
Atorvastatin
Current use	77	8.8	93	10.5	1.34	0.96 - 1.85	98	9.5	1.25	0.91 - 1.74
6mo - <5yrs	37	4.2	47	5.3	1.39	0.88 - 2.17	56	5.4	1.46	0.94 - 2.25
5yrs - <10yrs	28	3.2	26	2.9	1.01	0.58 - 1.77	24	2.3	0.85	0.48 - 1.51
≥ 10 yrs	12	1.4	20	2.3	1.97	0.94 - 4.11	18	1.7	1.55	0.73 - 3.30
p-value for trend					p = 0.048				p = 0.254
Simvastatin
Current use	50	5.7	49	5.5	0.97	0.64 - 1.48	57	5.5	1.05	0.70 - 1.57
6mo - <5yrs	30	3.4	29	3.3	0.93	0.54 - 1.58	35	3.4	1.03	0.62 - 1.72
5yrs - <10yrs	14	1.6	12	1.4	0.94	0.42 - 2.07	13	1.3	0.90	0.41 - 1.96
≥ 10 yrs	6	0.7	8	0.9	1.30	0.44 - 3.85	9	0.9	1.49	0.52 - 4.28
p-value for trend					p = 0.729				p = 0.681

OR: odds ratio adjusted for reference year, reference age, county of residence, and hormone therapy use